Drug Type Small molecule drug |
Synonyms hydroxycamptothecine, 羟基喜树碱 |
Target |
Action inhibitors |
Mechanism TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization- |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC20H16N2O5 |
InChIKeyHAWSQZCWOQZXHI-FQEVSTJZSA-N |
CAS Registry19685-09-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bladder Cancer | China | - | - |
Head and Neck Neoplasms | China | - | - |
Leukemia | China | - | - |
Liver Cancer | China | - | - |
Rectal Cancer | China | - | - |
Stomach Cancer | China | - | - |
Not Applicable | 29 | shvhqpouoc(yznaxzawiu) = rxxdrsjaja uykqmktdgp (fkxbizcfks ) View more | Positive | 26 Sep 2018 | |||
Chemotherapy combined with PCPH | shvhqpouoc(yznaxzawiu) = tnsdjjuhqo uykqmktdgp (fkxbizcfks ) View more | ||||||
Not Applicable | - | HCPT 8 mg/m^2 weekly | qvxdgejheg(waudhvmlqd) = ftltnqmbmy jhlnsrcipv (ztbibmjjxl ) | - | 01 Nov 2012 |